CoMentis Company

AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
Industry:
Regenerative medicine
Technology:
Stem Cell
Funding Status:
Late Stage Venture
Investment Stage:
N/A
Investors Number:
14
Headquarters:
United States
Employee Number:
51-100
Number Of Exists:
N/A
Investor Type:
N/A
Total Funding:
$107.5M
Founded Date:
2004
Last Funding Type:
Series E